Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (6): 1178-1182. doi: 10.19723/j.issn.1671-167X.2021.06.028

Previous Articles     Next Articles

Clinical analysis of testicular rhabdomyosarcoma

YE Jian-fei,ZHAO Lei,WANG Guo-liang,HONG Kai,MA Lu-lin()   

  1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
  • Received:2019-03-15 Online:2021-12-18 Published:2021-12-13
  • Contact: Lu-lin MA E-mail:malulin@bjmu.edu.cn
  • Supported by:
    Peking University Medicine Fund of Fostering Young Scholars’ Scientific & Technological Innovation(BMU2018PYB008);Key Clinical Projects of Peking University Third Hospital(BYSY2018047)

Abstract:

Testicular rhabdomyosarcoma is relatively rare in testicular tumors, but the age of patient is relatively young and the degree of malignancy is high. Therefore, this article introduces 4 cases of testicular rhabdomyosarcoma who were admitted to Peking University Third Hospital from May 1994 to February 2019, and reviews the literature to improve the diagnosis and treatment of this disease. The average age of the 4 patients was 17.5 years (14-21 years), the average hospital stay was 22.0 d (17-31 d), and the average body mass index was 19.6 kg/m2 (14.7-25.8 kg/m2). All the patients underwent routine preoperative blood and urine routine, biochemical tests, as well as serum tumor markers. Preoperative examinations also included chest radiograph, electrocardiogram, ultrasound of the scrotum and groin, and abdominal enhanced CT. Lung CT or other examinations were performed if necessary. The median serum human chorionic gonadotropin (HCG) of the 4 patients was 0.20 IU/L (0.06-0.86 IU/L) (all normal), and the median serum alpha-fetoprotein (AFP) was 1.03 g/L (0.65-1.66 g/L) (all normal). The average maximum diameter of the tumor was 10.0 cm (4.5-15.0 cm). Testicular rhabdomyosarcoma was mainly diagnosed by pathology. The main treatment was radical orchiectomy combined with retroperitoneal lymph node dissection, with or without postoperative adjuvant chemotherapy. The clinical manifestations of the patients with testicular rhabdomyosarcoma had no specific characteristics, but most patients were young at onset with mainly painless masses in the testicles, which were already large when they were found. Patients with testicular rhabdomyosarcoma have a poor prognosis, most of whom recur within two years. Because of the small number of cases of testicular rhabdomyosarcoma, there is no standard treatment currently. It is recommended that patients with testicular rhabdomyosarcoma undergo radical testicular resection combined with retroperitoneal lymph node dissection. Retroperitoneal lymph node metastasis is an important prognostic factor, and patients with postoperative adjuvant chemotherapy can still survive for a longer time. If local recurrence or limited metastasis is found after operation, local resection and salvage radiotherapy are feasible.

Key words: Testicular neoplasms, Rhabdomyosarcoma, Orchiectomy, Lymph node excision

CLC Number: 

  • R737.21

Table 1

Basic data of the patients of testicular rhabdomyosarcoma"

Items Case 1 Case 2 Case 3 Case 4
Basic data
Age/years 19 16 14 21
Hospital stay/d 21 17 31 19
BMI/(kg/m2) 22.03 16.02 25.83 14.67
Side Right Right Left Left
Chief complain Palpable mass in the right
scrotum for 1 month
Palpable mass in the right
scrotum for 6 months
Painful mass in the left
testis for 2 months
Palpable mass in the left
scrotum for 2 weeks
Perioperative data
HCG/(IU/L) 0.2 0.86 0.06
AFP/(μg/L) 0.65 0.76 1.30 1.65
LDH/(U/L) NA NA 0.68 146.00
Maximum dialater/cm 10.0 15.0 10.5 4.5
Approach Inguinal Inguinal Inguinal Inguinal
Surgery Radical orchiectomy Radical orchiectomy Radical orchiectomy Radical orchiectomy
RPLND No No Yes Yes
Follow-up Died 3 years later Relapse after 11 months Relapse twice after
17 months and 41 months
Alive without relapse

Figure 1

Ultrasonography of testicular rhabdomyosarcoma"

Figure 2

Pathology of testicular rhabdomyosarcoma(HE ×200)"

[1] 黄健, 王建业, 孔垂泽, 等. 中国泌尿外科和男科疾病诊断治疗指南[M]. 北京: 科学出版社, 2020: 145.
[2] Motzer RJ, Jonasch E, Agarwal N, et al. Testicular cancer, version 2.2015[J]. J Natl Compr Canc Netw, 2015, 13(6):772-799.
doi: 10.6004/jnccn.2015.0092
[3] Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer: 2015 Update[J]. Eur Urol, 2015, 68(6):1054-1068.
doi: 10.1016/j.eururo.2015.07.044 pmid: 26297604
[4] Yi J, Zhou DA, Huo JR, et al. Primary intratesticular rhabdomyosarcoma: A case report and literature review[J]. Oncol Lett, 2016, 11(2):1016-1020.
doi: 10.3892/ol.2015.3987
[5] Lovric E, Hizak DB, Balja MP, et al. An unusual mixed germ cell tumor of the testis consisting of rhabdomyosarcoma, mature teratoma and yolk sac tumor[J]. Asian J Androl, 2010, 12(3):451-452.
doi: 10.1038/aja.2010.2
[6] Korski K, Breborowicz D, Filas V, et al. A case of primary testi-cular germ cell tumor with rhabdomyosarcoma metastases as an example of applying the FISH method to diagnostic pathology[J]. APMIS, 2007, 115(11):1296-1301.
doi: 10.1111/apm.2007.115.issue-11
[7] Erbay ME, Tarhan F, Barisik NO, et al. A case of testicular rhabdomyosarcoma[J]. Int Urol Nephrol, 2004, 36(1):73-75.
doi: 10.1023/B:UROL.0000032671.74121.d3
[8] Gow KW, Murphy JR, Wu JK, et al. Metastatic testicular rhabdomyosarcoma: A report of two cases[J]. J Pediatr Surg, 2003, 38(8):E1-E3.
[9] Liu ZW, Zhang XQ, Hou GL, et al. Primary adult intratesticular rhabdomyosarcoma: Results of the treatment of six cases[J]. Int J Urol, 2011, 18(2):171-174.
doi: 10.1111/iju.2011.18.issue-2
[10] Banfield GK, Brookstein R. Rhabdomyosarcoma arising in teratoma of the testis[J]. J R Army Med Corps, 1995, 141(3):167-168.
doi: 10.1136/jramc-141-03-07
[11] Kelly B, Lundon D, Rowaiye B, et al. Embryonal rhabdomyosarcoma of the testis[J]. Can Urol Assoc J, 2011, 5(1):E7-E10.
[12] Nakagawa R, Aoyama S, Urata S, et al. Testicular rhabdomyosarcoma after chemotherapy for metastatic germ cell tumors[J]. Int Cancer Conf J, 2019, 8(4):175-180.
[13] Ishiguro N, Motoi T, Osaki M, et al. Immunohistochemical analysis of a muscle ankyrin-repeat protein, Arpp, in paraffin-embedded tumors: Evaluation of Arpp as a tumor marker for rhabdomyosarcoma[J]. Hum Pathol, 2005, 36(6):620-625.
pmid: 16021567
[14] Kumar S, Perlman E, Harris CA, et al. Myogenin is a specific marker for rhabdomyosarcoma: An immunohistochemical study in paraffin-embedded tissues[J]. Mod Pathol, 2000, 13(9):988-993.
doi: 10.1038/modpathol.3880179
[15] Walterhouse D, Watson A. Optimal management strategies for rhabdomyosarcoma in children[J]. Paediatr Drugs, 2007, 9(6):391-400.
doi: 10.2165/00148581-200709060-00006
[16] Breitfeld PP, Meyer WH. Rhabdomyosarcoma: New windows of opportunity[J]. Oncologist, 2005, 10(7):518-527.
pmid: 16079319
[17] Wiener ES, Anderson JR, Ojimba JI, et al. Controversies in the management of paratesticular rhabdomyosarcoma: Is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?[J]. Semin Pediatr Surg, 2001, 10(3):146-152.
pmid: 11481652
[18] Urgun DA, Bista B, Krishnam M. Unusual presentation of testicular rhabdomyosarcoma metastases to the right ventricle papillary muscle and tricuspid valve[J]. Radiol Case Rep, 2020, 15(9):1562-1565.
doi: 10.1016/j.radcr.2020.05.075
[19] Ferrari A, Casanova M, Massimino M, et al. The management of paratesticular rhabdomyosarcoma: A single institutional experience with 44 consecutive children[J]. J Urol, 1998, 159(3):1031-1034.
doi: 10.1016/S0022-5347(01)63830-8
[1] Guo-zhong LIN,Zhen-yu WANG,Bin LIU,Shao-min YANG. Intraspinal metastasis of alveolar rhabdomyosarcoma: A case report [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1165-1168.
[2] Jian-fei YE,Bing WANG,Lu-lin MA,Lei ZHAO,Guo-liang WANG,Kai HONG. Organ-sparing partial orchietectomy for testicular adenomatoid tumor [J]. Journal of Peking University(Health Sciences), 2019, 51(2): 365-368.
[3] HUA Ke-han, YANG Lei, ZHANG Xiao-wei, BAI Wen-jun, LI Qing, XU Tao. Complete androgen insensitivity syndrome associated with vesical fistula: a case report and literature review [J]. Journal of Peking University(Health Sciences), 2017, 49(4): 724-729.
[4] HAO Han, SU Xiao-hong, ZHENG Wei, GE Peng, HE Qun, SHEN Qi, YANG Xin-yu, ZHANG Zheng, LI Xue-song, LIN Jian, ZHOU Li-qun. Radical cystectomy in patients with pathological non-muscle invasive bladder cancer [J]. Journal of Peking University(Health Sciences), 2016, 48(4): 627-631.
[5] ZHANG Yu-jie, LIU Bao-guo, ZHAO Zhi-yan, SHENG Jin-dong, FENG Dong-dong. Relationship and clinical significance between mutated BRAF with prophylactic central-neck nodal dissection in papillary thyroid carcinoma [J]. Journal of Peking University(Health Sciences), 2016, 48(3): 502-506.
[6] MENG Yi-Sen, Su-Yang, Fan-Yu, Yu-Wei, Wang-Yu, Zheng-Wei, Chen-Cheng, Zhou-Li-Qun, Zhang-Qian, Li-Xue-Song, . Risk factors for the development of postoperative paralytic ileus after radical cystectomy: a report of 740 cases [J]. Journal of Peking University(Health Sciences), 2015, 47(4): 628-633.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2010, 42(1): 82 -84 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .